Risk of @entity0 recurrence in XXXX receiving @entity3329 : a hospital-based cohort study.

@entity1 @entity3329 @entity0 @entity5 @entity7273 @entity3
BACKGROUND: This retrospective cohort study evaluated whether @entity3329 ( @entity3329 ) therapy increases the risk of recurrence of @entity0 . METHODS: We analyzed 1,106 @entity1 who were diagnosed with stage 0-3 @entity0 between 2007 and 2011 and experienced remission after surgery and adjuvant therapy. The @entity1 were divided into two groups: group A (n=996), in which @entity1 did not participate in any @entity3329 therapy, regardless of whether they developed @entity0 ( @entity0 ) after @entity5 treatment; and group B (n=110), in which @entity1 participated in @entity3329 therapy for @entity0 . All @entity1 were monitored until October 2013 to determine whether @entity0 recurrence developed, including local or regional recurrence and distant @entity3 . @entity1 who developed @entity5 recurrence prior to @entity3329 therapy were excluded from analysis. Risk factors associated with @entity5 recurrence were evaluated using Cox proportional hazards models. RESULTS: During the monitoring period, 166 @entity1 (15.0%) developed @entity5 recurrence, including 154 (15.5%) in group A and 12 (10.9%) in group B. The median period from surgery to @entity5 recurrence was 1.85 (interquartile range 1.18-2.93) years. Independent risk factors for @entity5 recurrence were @entity5 histological grading of grade 3, high number (>= 3) of axillary lymph node invasion, and a large @entity5 size (>5 cm). Factors protecting against recurrence were positive @entity7273 status and receiving radiation therapy. Receiving @entity3329 therapy was not an outcome factor in multivariate analyses (hazard ratio 0.71, 95% confidence interval 0.39-1.29, P=0.259). CONCLUSION: @entity3329 is a gentle procedure that does not increase the risk of @entity0 recurrence in @entity1 who develop @entity0 .
